Phase 3
Vicadrostat (BI 690517) + empagliflozin: Aldosterone synthase inhibitor + SGLT2 inhibitor | HFpEF
Indication: Heart failure with preserved ejection fraction
Boehringer Ingelheim is developing vicadrostat (BI 690517), a novel selective and potent aldosterone synthase inhibitor (ASi) for people living with heart failure with preserved ejection fraction (HFpEF) that is designed to work by effectively and sustainably inhibiting aldosterone synthase and the subsequent production of aldosterone.
The trial is investigating the efficacy and safety profile of vicadrostat given in combination with empagliflozin, compared to placebo and empagliflozin on top of standard of care.
Vicadrostat is part of Boehringer Ingelheim’s research and development portfolio in the cardiovascular, renal, metabolic disease area.